Xencor (XNCR) Income from Continuing Operations (2013 - 2026)
Xencor's (XNCR) quarterly Income from Continuing Operations came in at 128936000.0 in Q1 2026, down 164.95% year-on-year from 198527825.1 in Q1 2025, and down 1838.01% on a QoQ basis from 6653000.0 in Q4 2025.
Xencor (XNCR) Income from Continuing Operations (2013 - 2026) Analysis & Trends
Xencor (XNCR) has 14 years of Income from Continuing Operations data on file, last reported at 128936000.0 in Q1 2026.
- On a quarterly basis, Income from Continuing Operations fell 164.95% year-over-year to 128936000.0 in Q1 2026; TTM through Mar 2026 was 172441000.0, a 18.31% increase from a year earlier, with the FY2025 full-year figure at 92137000.0, up 61.05% from the prior year.
- Income from Continuing Operations for Q1 2026 stood at 128936000.0, down from 6653000.0 in the prior quarter.
- Over the last five years, Income from Continuing Operations for XNCR reached as high as 25782000.0 in Q1 2022 and fell as low as 128936000.0 in Q1 2026.
- Historically, Income from Continuing Operations has averaged 42206411.76 across 5 years, with a median of 46200000.0 in 2024.
- Across the five-year window, Income from Continuing Operations surged 259.43% in 2022 and plunged 327.17% in 2023, its largest moves.
- Year by year, Income from Continuing Operations stood at 12042000.0 in 2022, then sank by 118.49% to 26310000.0 in 2023, then sank by 75.6% to 46200000.0 in 2024, then surged by 85.6% to 6653000.0 in 2025, then plunged by 1838.01% to 128936000.0 in 2026.
- Per Business Quant data, the three most recent Income from Continuing Operations figures were 128936000.0 in Q1 2026, 6653000.0 in Q4 2025, and 6027000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -37.09 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 227.36 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -3.68 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 727.20 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | -26.94 Mn |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 362.00 Mn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -453.82 Mn |
| 10 | Xencor | 1.47 Bn | 1.09 Bn | - | -128.94 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -128.94 Mn |
| Dec 31, 2025 | -6.65 Mn |
| Sep 30, 2025 | -6.03 Mn |
| Jun 30, 2025 | -30.83 Mn |
| Mar 31, 2025 | -48.67 Mn |
| Dec 31, 2024 | -46.20 Mn |
| Sep 30, 2024 | -47.44 Mn |
| Jun 30, 2024 | -68.78 Mn |
| Mar 31, 2024 | -74.12 Mn |
| Dec 31, 2023 | -26.31 Mn |
| Sep 30, 2023 | -24.27 Mn |
| Jun 30, 2023 | -71.11 Mn |
| Mar 31, 2023 | -58.57 Mn |
| Dec 31, 2022 | -12.04 Mn |
| Sep 30, 2022 | -32.76 Mn |
| Jun 30, 2022 | -60.59 Mn |
| Mar 31, 2022 | 25.78 Mn |
| Dec 31, 2021 | 73.06 Mn |
| Sep 30, 2021 | -40.19 Mn |
| Jun 30, 2021 | -56.30 Mn |